Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study.
Yutaka SeinoDae-Jung KimDaisuke YabeElise Chia-Hui TanWook-Jin ChungKyoung Hwa HaMasaomi NangakuKoichi NodeRiho KlementAtsutaka YasuiWei-Yu LeiSunwoo LeeMoe H KyawAnouk Déruaz-LuyetKimberly G BrodoviczWayne Huey Herng Sheunull nullPublished in: Endocrinology, diabetes & metabolism (2020)
Empagliflozin treatment was associated with reduced risk for HHF, all-cause mortality and ESRD compared with DPP-4 inhibitors in routine clinical practice in Japan, South Korea and Taiwan.